Acute Flaccid Paralysis in a Vaccinated Child With Primary Immunodeficiency: Difficulties With Diagnostics of Vaccine‐Associated Paralytic Poliomyelitis
Authors:
- Armen K. ShakaryanASArmen K. Shakaryan
- Yulia M. MikhailovaYMYulia M. Mikhailova
- Alina V. ChirovaACAlina V. Chirova
- Evgeniya A. CherepanovaECEvgeniya A. Cherepanova
- Olga Y. BaikovaOBOlga Y. Baikova
- Elizaveta V. YakovchukEYElizaveta V. Yakovchuk
- Evgenia V. KarpovaEKEvgenia V. Karpova
- Aleksander P. IvanovAIAleksander P. Ivanov
- Tatiana E. SnitkovskayaTSTatiana E. Snitkovskaya
- Artyom A. BasovABArtyom A. Basov
- Olga V. TsvirkunOTOlga V. Tsvirkun
- 25 November 2025
- journal article
- case report
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (12) , e70704
Abstract
Oral polio vaccine (OPV) from attenuated Sabin strains widely used for poliomyelitis prevention and eradication along with undeniable advantages has significant disadvantages, one of which is the ability to cause cases of vaccine‐associated paralytic poliomyelitis (VAPP). Inactivated poliovirus vaccine (IPV) introduction into the national immunization schedules of countries that continue to use OPV allows effective prevention of VAPP cases and simultaneously forms immunity to PV type 2. The present study presents an example of VAPP development in a child with Bruton's disease, born by in vitro fertilization, vaccinated with four IPV doses followed by one bOPV dose, and paralysis onset 52 days bOPV vaccination. Despite objective clinical, laboratory and instrumental signs of anterior corneal myelitis, the isolation of Sabin‐like poliovirus, and contradictory results of serological investigation, diagnostics caused significant difficulties for the treating physicians. The case was associated with a recombinant poliovirus of vaccine Sabin strains types 3 and 1 with a recombination point in 2C‐encoding genome region, containing known neurovirulence reverse mutations and some unique ones. The introduction of IPV doses for primary immunization increases the safety of immunization against polio; however, while OPV is in use there is still a VAPP threat for immunocompromised children and unvaccinated contacts.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation
This publication has 30 references indexed in Scilit:
- Vaccine-associated paralytic poliomyelitis in a child: fast transformation from Sabin-like virus to vaccine-derived poliovirus triggered an epidemiological response in two countries of the European regionInternational Journal of Infectious Diseases, 2022
- X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the worldWorld Allergy Organization Journal, 2019
- Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998–2014International Journal of Infectious Diseases, 2018
- Vaccine associated paralytic poliomyelitis unmasking common variable immunodeficiencyIndian Pediatrics, 2017
- Vaccine-Derived Poliomyelitis 12 Years after Infection in MinnesotaNew England Journal of Medicine, 2011
- Recurrent isolation of poliovirus 3 strains with chimeric capsid protein Vp1 suggests a recombination hot-spot site in Vp1Virus Research, 2010
- Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemiaVirus Research, 2008
- Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient manThe Lancet, 2004
- Microarray analysis of evolution of RNA viruses: Evidence of circulation of virulent highly divergent vaccine-derived poliovirusesProceedings of the National Academy of Sciences, 2003
- Consistent selection of mutations in the 5′‐untranslated region of oral poliovirus vaccine upon passaging in vitroJournal of Medical Virology, 1994